Patients and the head of Saskatchewan’s Epilepsy Program are calling on the Saskatchewan Party to resume talks for the public coverage of Xcopri, a crucial anti-seizure medication that has transformed the lives of many people living with epilepsy.
The Saskatchewan Party abruptly ended talks in October 2024, disregarding recommendations from local medical professionals and patient advocates. This move has sparked concern among those who rely on the medication and experts who believe it is a necessary step for improving the quality of life for individuals with drug-resistant epilepsy.
The Sask. Party needs to stop ignoring our healthcare workers and make this medication available for people suffering from seizures,” said Vicki Mowat, Shadow Minister for Health. “After 17 years of the Sask. Party, our province ranks last in healthcare in Canada. We have a chance to lead again by listening to healthcare workers and supporting this life-saving medication.”
Xcopri has shown significant promise in reducing or even eliminating seizures in patients who have not responded to other treatments. The cost of Xcopri is comparable to or even lower than other epilepsy medications that are already covered by the province’s drug plans.
The Canadian League Against Epilepsy, which represents more than 200 neurologists, epileptologists, and other healthcare professionals, is voicing its support for the reinstatement of talks. The league is urging the Saskatchewan Party to reconsider its position and prioritize the health and well-being of the province’s epilepsy patients.
Dr. Alexandra Carter, a neurologist and epileptologist, are also speaking out in favor of public coverage for the medication. Dr. Carter, who serves as the Medical Director of the Saskatchewan Epilepsy Program with the Saskatchewan Health Authority and the University of Saskatchewan, highlighted the significant improvements in patients' lives following treatment with Xcopri.
“I have seen significant seizure reduction and even seizure freedom in my patients who take Xcopri. These patients are drug-resistant, which means they’ve all failed multiple treatments,” said Dr. Carter. “For years, these patients have been living with uncontrolled seizures and had little hope of achieving a better quality of life – now, they are experiencing life-changing results. You can’t put a price on that and yet cost remains a significant barrier for many who qualify for this treatment.”
As the issue continues to gain attention, patients and healthcare professionals are urging the Saskatchewan Party to re-engage in discussions about public coverage for Xcopri, stressing that this medication offers hope and improved quality of life for those who have exhausted all other treatment options.